US2021069222A1PendingUtilityA1
Treatment of metabolic disorders in equine animals
Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBHPriority: Apr 4, 2013Filed: Nov 10, 2020Published: Mar 11, 2021
Est. expiryApr 4, 2033(~6.7 yrs left)· nominal 20-yr term from priority
A61P 3/10A61P 3/08A61P 3/04A61K 31/381A61K 31/357A61K 9/0053A61K 31/7042C07H 15/207A61K 9/0019A61K 47/545A61K 9/0031A61P 3/00C07D 309/10A61K 31/7048A61K 9/2018A61K 9/4866A61K 9/20A61K 9/48A61K 31/7034A61K 31/70A61K 31/7056A61K 31/351A61K 9/02
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.